Bile Duct Tumors Medication

1. Smits NJ, Reeders JW. Imaging and staging of biliopancreatic malignancy: role of ultrasound. Ann Oncol. 1999. 10 Suppl 4:20-4. [Medline].

2. Keane MG, Pereira SP. Improving detection and treatment of liver cancer. Practitioner. 2013 Jul-Aug. 257 (1763):21-6, 2-3. [Medline].

3. Saurin JC, Joly-Pharaboz MO, Pernas P, Henry L, Ponchon T, Madjar JJ. Detection of Ki-ras gene point mutations in bile specimens for the differential diagnosis of malignant and benign biliary strictures. Gut. 2000 Sep. 47 (3):357-61. [Medline]. [Full Text].

4. Rijken AM, Offerhaus GJ, Polak MM, Gouma DJ, van Gulik TM. p53 expression as a prognostic determinant in resected distal bile duct carcinoma. Eur J Surg Oncol. 1999 Jun. 25 (3):297-301. [Medline].

5. Nakanuma Y, Miyata T, Uchida T. Latest advances in the pathological understanding of cholangiocarcinomas. Expert Rev Gastroenterol Hepatol. 2016. 10 (1):113-27. [Medline].

6. Elfaki DH, Gossard AA, Lindor KD. Cholangiocarcinoma: expanding the spectrum of risk factors. J Gastrointest Cancer. 2008. 39 (1-4):114-7. [Medline].

7. Chapman RW. Risk factors for biliary tract carcinogenesis. Ann Oncol. 1999. 10 Suppl 4:308-11. [Medline].

8. Chan-On W, Nairismägi ML, Ong CK, Lim WK, Dima S, Pairojkul C, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013 Dec. 45 (12):1474-8. [Medline].

9. Petrick JL, Yang B, Altekruse SF, Van Dyke AL, Koshiol J, Graubard BI, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: A population-based study in SEER-Medicare. PLoS One. 2017. 12 (10):e0186643. [Medline]. [Full Text].

10. Doussot A, Groot-Koerkamp B, Wiggers JK, Chou J, Gonen M, DeMatteo RP, et al. Outcomes after Resection of Intrahepatic Cholangiocarcinoma: External Validation and Comparison of Prognostic Models. J Am Coll Surg. 2015 Aug. 221 (2):452-61. [Medline].

11. Freeny PC. Computed tomography in the diagnosis and staging of cholangiocarcinoma and pancreatic carcinoma. Ann Oncol. 1999. 10 Suppl 4:12-7. [Medline].

12. Tani K, Kubota Y, Yamaguchi T, Kitagawa S, Katoh T, Seki T, et al. MR imaging of peripheral cholangiocarcinoma. J Comput Assist Tomogr. 1991 Nov-Dec. 15 (6):975-8. [Medline].

13. Kim HJ, Lee JM, Kim SH, Han JK, Lee JY, Choi JY, et al. Evaluation of the longitudinal tumor extent of bile duct cancer: value of adding gadolinium-enhanced dynamic imaging to unenhanced images and magnetic resonance cholangiography. J Comput Assist Tomogr. 2007 May-Jun. 31 (3):469-74. [Medline].

14. Hänninen EL, Pech M, Jonas S, Ricke J, Thelen A, Langrehr J, et al. Magnetic resonance imaging including magnetic resonance cholangiopancreatography for tumor localization and therapy planning in malignant hilar obstructions. Acta Radiol. 2005 Aug. 46 (5):462-70. [Medline].

15. Sakai Y, Tsuyuguchi T, Tsuchiya S, Fukuda Y, Miyakawa K, Sugiyama H, et al. Clinical utility of peroral cholangioscopy for mucin-producing bile duct tumor. Hepatogastroenterology. 2008 Sep-Oct. 55 (86-87):1509-12. [Medline].

16. Han NY, Kim JY, Kim MJ, Park BJ, Sung DJ, Sim KC, et al. Validation of Feasibility of Magnetic Resonance Imaging for the Measurement of Depth of Tumor Invasion in Distal Bile Duct Cancer According to the New American Joint Committee on Cancer Staging System. Acad Radiol. 2017 Dec. 24 (12):1526-1534. [Medline].

17. Choi JH, Lee SK. Percutaneous transhepatic cholangioscopy: does its role still exist?. Clin Endosc. 2013 Sep. 46 (5):529-36. [Medline]. [Full Text].

18. Rumalla A, Baron TH. Evaluation and endoscopic palliation of cholangiocarcinoma. Management of cholangiocarcinoma. Dig Dis. 1999. 17 (4):194-200. [Medline].

19. Desa LA, Akosa AB, Lazzara S, Domizio P, Krausz T, Benjamin IS. Cytodiagnosis in the management of extrahepatic biliary stricture. Gut. 1991 Oct. 32 (10):1188-91. [Medline]. [Full Text].

20. Furmanczyk PS, Grieco VS, Agoff SN. Biliary brush cytology and the detection of cholangiocarcinoma in primary sclerosing cholangitis: evaluation of specific cytomorphologic features and CA19-9 levels. Am J Clin Pathol. 2005 Sep. 124 (3):355-60. [Medline]. [Full Text].

21. Lamerz R. Role of tumour markers, cytogenetics. Ann Oncol. 1999. 10 Suppl 4:145-9. [Medline].

22. [Guideline] NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. Version 1.2020. National Comprehensive Cancer Network. Available at https://www.nccn.org/professionals/physician_gls/PDF/hepatobiliary.pdf. March 23, 2020; Accessed: April 20, 2020.

23. Todoroki T. Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery. Hepatogastroenterology. 2000 May-Jun. 47 (33):644-9. [Medline].

24. Oh D, Lim DH, Heo JS, Choi SH, Choi DW, Ahn YC, et al. The role of adjuvant radiotherapy in microscopic tumor control after extrahepatic bile duct cancer surgery. Am J Clin Oncol. 2007 Feb. 30 (1):21-5. [Medline].

25. Pitt HA, Nakeeb A, Abrams RA, Coleman J, Piantadosi S, Yeo CJ, et al. Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg. 1995 Jun. 221 (6):788-97; discussion 797-8. [Medline]. [Full Text].

26. Ma KW, Cheung TT, Leung B, She BWH, Chok KSH, Chan ACY, et al. Adjuvant chemotherapy improves oncological outcomes of resectable intrahepatic cholangiocarcinoma: A meta-analysis. Medicine (Baltimore). 2019 Feb. 98 (5):e14013. [Medline]. [Full Text].

27. Ferrero A, Lo Tesoriere R, Viganò L, Caggiano L, Sgotto E, Capussotti L. Preoperative biliary drainage increases infectious complications after hepatectomy for proximal bile duct tumor obstruction. World J Surg. 2009 Feb. 33 (2):318-25. [Medline].

28. Gerhards MF, Gonzalez DG, ten Hoopen-Neumann H, van Gulik TM, de Wit LT, Gouma DJ. Prevention of implantation metastases after resection of proximal bile duct tumours with pre-operative low dose radiation therapy. Eur J Surg Oncol. 2000 Aug. 26 (5):480-5. [Medline].

29. Ortner MA. Photodynamic therapy of cholangiocarcinoma cancer. Gastrointest Endosc Clin N Am. 2000 Jul. 10 (3):481-6. [Medline].

30. Nanashima A, Hiyoshi M, Imamura N, Hamada T, Nishida T, Kawakami H, et al. Two cases of bile duct carcinoma patients who underwent the photodynamic therapy using talaporfin sodium (Laserphyrin^®). Clin J Gastroenterol. 2020 Feb. 13 (1):102-109. [Medline].

31. Smith I, Kahaleh M. Biliary Tumor Ablation with Photodynamic Therapy and Radiofrequency Ablation. Gastrointest Endosc Clin N Am. 2015 Oct. 25 (4):793-804. [Medline].

32. Buerlein RCD, Wang AY. Endoscopic Retrograde Cholangiopancreatography-Guided Ablation for Cholangiocarcinoma. Gastrointest Endosc Clin N Am. 2019 Apr. 29 (2):351-367. [Medline].

33. Jeyarajah DR, Klintmalm GB. Is liver transplantation indicated for cholangiocarcinoma?. J Hepatobiliary Pancreat Surg. 1998. 5 (1):48-51. [Medline].

34. Kawamoto H, Ishida E, Okamoto Y, Okada H, Sakaguchi K, Nakagawa M, et al. Evaluation of covered metallic stents in malignant biliary stenosis--prominent effectiveness in gallbladder carcinoma. Hepatogastroenterology. 2005 Sep-Oct. 52 (65):1351-6. [Medline].

35. Saleem A, Leggett CL, Murad MH, Baron TH. Meta-analysis of randomized trials comparing the patency of covered and uncovered self-expandable metal stents for palliation of distal malignant bile duct obstruction. Gastrointest Endosc. 2011 Aug. 74 (2):321-327.e1-3. [Medline].

36. Schinzari G, Rossi E, Mambella G, Strippoli A, Cangiano R, Mutignani M, et al. First-line Treatment of Advanced Biliary Ducts Carcinoma: A Randomized Phase II Study Evaluating 5-FU/LV Plus Oxaliplatin (Folfox 4) Versus 5-FU/LV (de Gramont Regimen). Anticancer Res. 2017 Sep. 37 (9):5193-5197. [Medline]. [Full Text].

37. Jung CFM, Lavole J, Barret M, Abou Ali E, Palmieri LJ, Dermine S, et al. Local Therapy in Advanced Cholangiocarcinoma: A Review of Current Endoscopic, Medical, and Oncologic Treatment Options. Oncology. 2019. 97 (4):191-201. [Medline].

38. Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020 Mar 20. [Medline].

39. Kosuge T, Yamamoto J, Shimada K, Yamasaki S, Makuuchi M. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg. 1999 Nov. 230 (5):663-71. [Medline]. [Full Text].

40. Havlik R, Sbisà E, Tullo A, Kelly MD, Mitry RR, Jiao LR, et al. Results of resection for hilar cholangiocarcinoma with analysis of prognostic factors. Hepatogastroenterology. 2000 Jul-Aug. 47 (34):927-31. [Medline].

41. Levi Sandri GB, Spoletini G, Mascianà G, Colasanti M, Lepiane P, Vennarecci G, et al. The role of minimally invasive surgery in the treatment of cholangiocarcinoma. Eur J Surg Oncol. 2017 Sep. 43 (9):1617-1621. [Medline].

Todd A Nickloes, DO, FACOS Associate Professor, Department of Surgery, Division of Trauma/Critical Care, University of Tennessee Medical Center-Knoxville

Todd A Nickloes, DO, FACOS is a member of the following medical societies: American Medical Association, American Osteopathic Association, Association for Academic Surgery, Society of Critical Care Medicine, Society of Laparoendoscopic Surgeons, Southeastern Surgical Congress, Southern Medical Association, Eastern Association for the Surgery of Trauma, American College of Osteopathic Surgeons

Disclosure: Nothing to disclose.

Brian Reed, MD Staff Physician, Department of Surgery, University of Tennessee Medical Center

Brian Reed, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Surgeons, American Medical Association

Disclosure: Nothing to disclose.

LaMar O Mack, MD Resident Physician, Department of Surgery, University of Tennessee Medical Center

LaMar O Mack, MD is a member of the following medical societies: American Urological Association, National Medical Association, Student National Medical Association

Disclosure: Nothing to disclose.

Ravi Pokala Kiran, MBBS, MS, FRCS 

Disclosure: Nothing to disclose.

Naveen Pokala, MBBS, MS, FRCS 

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

John Geibel, MD, MSc, DSc, AGAF Vice Chair and Professor, Department of Surgery, Section of Gastrointestinal Medicine, Professor, Department of Cellular and Molecular Physiology, Yale University School of Medicine; Director of Surgical Research, Department of Surgery, Yale-New Haven Hospital; American Gastroenterological Association Fellow; Fellow of the Royal Society of Medicine

John Geibel, MD, MSc, DSc, AGAF is a member of the following medical societies: American Gastroenterological Association, American Physiological Society, American Society of Nephrology, Association for Academic Surgery, International Society of Nephrology, New York Academy of Sciences, Society for Surgery of the Alimentary Tract

Disclosure: Nothing to disclose.

Marc D Basson, MD, PhD, MBA, FACS Senior Associate Dean for Medicine and Research, Professor of Surgery, Pathology, and Biomedical Sciences, University of North Dakota School of Medicine and Health Sciences

Marc D Basson, MD, PhD, MBA, FACS is a member of the following medical societies: Alpha Omega Alpha, American College of Surgeons, American Gastroenterological Association, Phi Beta Kappa, Sigma Xi

Disclosure: Nothing to disclose.

Richard E Glass, MBBS, MS, FRCS Consultant General and Gastrointestinal Surgeon, Department of Gastrointestinal and General Surgery, Princess Margaret Hospital, UK

Disclosure: Nothing to disclose.

Michael A Grosso, MD Consulting Staff, Department of Cardiothoracic Surgery, St Francis Hospital

Michael A Grosso, MD is a member of the following medical societies: American College of Surgeons, Society of Thoracic Surgeons, and Society of University Surgeons

Disclosure: Nothing to disclose.

Carol EH Scott-Conner, MD, PhD Professor, Department of Surgery, University of Iowa College of Medicine

Carol Eh Scott-Conner is a member of the following medical societies: American Association for Cancer Research, American Association for the Surgery of Trauma, American Burn Association, American Cancer Society, American College of Gastroenterology, American College of Surgeons, American Medical Association, American Society for Gastrointestinal Endoscopy, Association for Academic Surgery, Association for Surgical Education,Association of VA Surgeons, Iowa Medical Society, Sigma Xi, Society for Surgery of the Alimentary Tract, Society of American Gastrointestinal and Endoscopic Surgeons, Society of Critical Care Medicine, Society of Surgical Oncology, Society of University Surgeons, and Southeastern Surgical Congress

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article